Company

Product Platforms

The different products of CellGenix can be classified into three strategic platforms:

• Ex Vivo Therapeutics
• Cellular Therapeutics
• Molecular Therapeutics

---

Ex Vivo Therapeutics

Medical devices, tools and reagents for clinical ex vivo cell processing. Ancillary materials for clinical cell therapy applications require highest quality standards. CellGenix has extensive experience in the field of GMP-compliant ex vivo cell processing tools as well as strong concurrent regulatory expertise (i.e. various FDA Drug Master Files).

CellGro® GMP Cytokines CellGro® Research Cytokines CellGro® Serum-free Media CellGro® Closed Kit Systems VueLife™ Culture Bags

---

Cellular Therapeutics

These are cell based medicinal products for cancer therapy and tissue repair, manufactured and processed under GMP conditions. Over a decade of experience (first European manufacturing license in 1995) accumulates in our comprehensive product and process know-how.This currently comprises:

Metreon autologous and allogenic cord blood cell preparations Metreon autologous chondrocyte transplantation (CartiGro® ACT)

---

Molecular Therapeutics

The production of human recombinant biologics by E.coli fermentation is the main focus of MTX. This currently comprises a patient-specific biopharmaceutical vaccine, produced with recombinant technology and manufactured under GMP (in phase II clinical trials) as well as various human recombinant GMP cytokines produced for the clinical cell therapy market.

" Non-Hodgkin´s B-cell lymphoma idiotype vaccine (IdioVax®)

CellGro^® is a registered trade mark of CellGenix in several European countries and Japan.
In the U.S.A. and Canada CellGro^® products are distributed under the name of CellGenix™.